Table 1 A clinical profile of subjects
From: Global Thrombosis Test – a possible monitoring system for the effects and safety of dabigatran
Age | 76.5 ± 1.4 |
Male sex, N (%) | 27 (62.8 %) |
Follow up period (months) | 14.7 ± 1.6 |
CHA2DS2 –VASc score, N (%) | |
0 or 1 point | 3 (7.0 %) |
2 points | 3 (7.0 %) |
3 points | 11 (25.5 %) |
≥ 4 points | 26 (60.5 %) |
HAS-BLED Score, N (%) | |
0 point | 4 (9.3 %) |
1 point | 13 (30.2 %) |
2 points | 12 (27.9 %) |
≥ 3 points | 14 (32.6 %) |
Hypertension, N (%) | 28 (65.1 %) |
Diabetes, N (%) | 12 (27.9 %) |
Dyslipidemia, N (%) | 31 (69.8 %) |
Concomitantly taking anti-platelets | |
Aspirin, N (%) | 21 (48.8 %) |
Clopidogrel, N (%) | 2 (4.7 %) |